Market capitalization | $44.24b |
Enterprise Value | $56.01b |
P/E (TTM) P/E ratio | 31.47 |
EV/FCF (TTM) EV/FCF | 30.66 |
EV/Sales (TTM) EV/Sales | 3.69 |
P/S ratio (TTM) P/S ratio | 2.92 |
P/B ratio (TTM) P/B ratio | 6.59 |
Revenue growth (TTM) Revenue growth | 3.45% |
Revenue (TTM) Revenue | $15.16b |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
27 Analysts have issued a IQVIA forecast:
27 Analysts have issued a IQVIA forecast:
Dec '23 |
+/-
%
|
||
Net Profit | 1,358 1,358 |
24%
24%
|
|
Depreciation and Amortization | 1,125 1,125 |
0%
0%
|
|
Stock Compensation | 217 217 |
12%
12%
|
|
Operating Cash Flow | 2,149 2,149 |
5%
5%
|
|
Investments | 649 649 |
4%
4%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | 1,500 1,500 |
5%
5%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Provides biopharmaceutical development services and commercial outsourcing services
Head office | United States |
CEO | Ari Bousbib |
Employees | 87,000 |
Founded | 1950 |
Website | www.iqvia.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.